ES2434853B1 - Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos - Google Patents
Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos Download PDFInfo
- Publication number
- ES2434853B1 ES2434853B1 ES201230919A ES201230919A ES2434853B1 ES 2434853 B1 ES2434853 B1 ES 2434853B1 ES 201230919 A ES201230919 A ES 201230919A ES 201230919 A ES201230919 A ES 201230919A ES 2434853 B1 ES2434853 B1 ES 2434853B1
- Authority
- ES
- Spain
- Prior art keywords
- methods
- stem cell
- therapeutic
- mir
- molecular marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos.#La presente invención se relaciona con métodos para determinar la capacidad inmunorreguladora de una célula madre, basándose en los niveles de expresión del microARN miR-335. Adicionalmente, la invención también se relaciona con métodos in vitro para incrementar la capacidad inmunorreguladora de una célula madre, en donde dichos métodos comprenden tratar dicha célula madre con un inhibidor de miR-335. Finalmente, la invención se relaciona con usos y métodos terapéuticos para tratar a un sujeto con una enfermedad autoinmune, una enfermedad inflamatoria, la enfermedad de injerto contra huésped, o una enfermedad que requiera la inducción de tolerancia a un trasplante o la regeneración y/o reparación de tejidos, comprendiendo dichos usos y métodos terapéuticos la administración de una célula madre que presenta niveles reducidos de expresión y/o actividad de miR-335.
Description
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230919A ES2434853B1 (es) | 2012-06-12 | 2012-06-12 | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
PCT/ES2013/070381 WO2013186418A1 (es) | 2012-06-12 | 2013-06-12 | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230919A ES2434853B1 (es) | 2012-06-12 | 2012-06-12 | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2434853A1 ES2434853A1 (es) | 2013-12-17 |
ES2434853B1 true ES2434853B1 (es) | 2014-09-30 |
Family
ID=49034107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201230919A Withdrawn - After Issue ES2434853B1 (es) | 2012-06-12 | 2012-06-12 | Marcador molecular de potencia terapéutica de células madre mesenquimales humanas y sus usos |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2434853B1 (es) |
WO (1) | WO2013186418A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11096967B2 (en) * | 2016-02-26 | 2021-08-24 | Scm Lifescience Co., Ltd. | Pharmaceutical composition for preventing or treating regulatory T cell-mediated diseases |
CN111979187B (zh) * | 2020-08-21 | 2022-04-08 | 遵义医科大学附属医院 | 一种抗人间充质干细胞衰老及增强其干性特征的方法 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
JP2909216B2 (ja) | 1994-04-29 | 1999-06-23 | パーキン‐エルマー コーポレイション | 核酸増幅生成物のリアルタイム検出装置 |
WO1997014028A2 (en) | 1995-10-11 | 1997-04-17 | Luminex Corporation | Multiplexed analysis of clinical specimens apparatus and method |
US6057134A (en) | 1996-10-07 | 2000-05-02 | Ambion, Inc. | Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides |
WO1998035012A2 (en) | 1997-02-12 | 1998-08-13 | Chan Eugene Y | Methods and products for analyzing polymers |
US6365731B1 (en) | 1997-08-06 | 2002-04-02 | Ambion, Inc. | Stripping nucleic acids with iodine and sodium thiosulfate |
KR20010031140A (ko) | 1997-10-14 | 2001-04-16 | 루미넥스 코포레이션 | 정밀 형광염료 입자 및 그의 제조방법 그리고 그의 사용 |
US6458583B1 (en) | 1998-09-09 | 2002-10-01 | Agilent Technologies, Inc. | Method and apparatus for making nucleic acid arrays |
US6461812B2 (en) | 1998-09-09 | 2002-10-08 | Agilent Technologies, Inc. | Method and multiple reservoir apparatus for fabrication of biomolecular arrays |
US6436640B1 (en) | 1999-03-18 | 2002-08-20 | Exiqon A/S | Use of LNA in mass spectrometry |
US6465183B2 (en) | 1999-07-01 | 2002-10-15 | Agilent Technologies, Inc. | Multidentate arrays |
US6461816B1 (en) | 1999-07-09 | 2002-10-08 | Agilent Technologies, Inc. | Methods for controlling cross-hybridization in analysis of nucleic acid sequences |
ATE412184T1 (de) | 1999-08-17 | 2008-11-15 | Luminex Corp | Verfahren zur analyse einer mehrzahl von proben verschiedenen ursprungs auf einen analyten |
US7122303B2 (en) | 1999-09-17 | 2006-10-17 | Agilent Technologies, Inc. | Arrays comprising background features that provide for a measure of a non-specific binding and methods for using the same |
US6428957B1 (en) | 1999-11-08 | 2002-08-06 | Agilent Technologies, Inc. | Systems tools and methods of assaying biological materials using spatially-addressable arrays |
CA2459347C (en) | 2001-09-04 | 2012-10-09 | Exiqon A/S | Locked nucleic acid (lna) compositions and uses thereof |
GB0918615D0 (en) * | 2009-10-23 | 2009-12-09 | Cellerix Sa | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
-
2012
- 2012-06-12 ES ES201230919A patent/ES2434853B1/es not_active Withdrawn - After Issue
-
2013
- 2013-06-12 WO PCT/ES2013/070381 patent/WO2013186418A1/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2013186418A1 (es) | 2013-12-19 |
WO2013186418A9 (es) | 2014-04-17 |
ES2434853A1 (es) | 2013-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2533145B1 (es) | Procedimiento cosmético para reducir el tejido adiposo subcutáneo | |
CO2018003678A2 (es) | Composiciones y métodos para inhibir la expresión génica de lpa | |
BR112014031874A2 (pt) | método para preparar células-tronco em concentração elevada | |
ES2721180T3 (es) | Productos terapéuticos usando células adiposas y secreciones celulares | |
WO2014028493A3 (en) | Exosomes and micro-ribonucleic acids for tissue regeneration | |
CU24495B1 (es) | Compuestos que expanden las células hematopoyéticas y método ex vivo para expandir las células hematopoyéticas | |
AR087842A1 (es) | Fitocanabinoides que pueden usarse en el tratamiento del cancer | |
CL2015000529A1 (es) | Inhibidores de glucosilceramida sintasa. | |
DOP2013000025A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
CL2010000710A1 (es) | Uso de una canula para la irradiacion de un objetivo en un ojo,en que la canula esta configurada ser insertada en un espacio potencial debajo de la capsula de tenon del ojo, la insercion de la canula permite la observacion a traves de la pupila, puede ser ajustada y permite la irradiacion del objetivo con rbs. | |
CO7200273A2 (es) | Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
BR112018003031A2 (pt) | formulações clínicas | |
WO2013124815A3 (en) | Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof | |
CL2015002753A1 (es) | Matriz de colágeno repoblada de células para reparación y regeneración del tejido blando | |
MX363000B (es) | Composiciones y usos de las mismas para tratar la inflamación. | |
NI201500063A (es) | Tratamiento de cáncer con pomalidomida en un individuo con daño renal | |
BR112017017886A2 (pt) | gerando populações de células endoteliais arteriais | |
CY1124195T1 (el) | Συμπληρωματικα θεραπευτικα σκευασματα για την διαδοχικη ή ξεχωριστη χορηγηση βουτυρικου οξεος και προβιοτικων | |
WO2014138315A8 (en) | Heparanase expression in human t lymphocytes | |
BR112016029558A2 (pt) | terapia de células-tronco em patologias endometriais | |
CR20150310A (es) | Solución para preservar conductos vasculares | |
BR112014019660A8 (pt) | Peça de polo | |
AR108134A1 (es) | Diferenciación de células madre pluripotentes en células del endodermo del intestino medio | |
CL2016001510A1 (es) | Células madre derivadas de musculo de mamifero | |
CL2015003402A1 (es) | Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2434853 Country of ref document: ES Kind code of ref document: B1 Effective date: 20140930 |
|
FA2A | Application withdrawn |
Effective date: 20150209 |